The National Comprehensive Cancer Network (NCCN) Guidelines now recommend scalp cooling as a category 2A treatment option for patients with invasive breast cancer

PAXMAN today announce that the National Comprehensive Cancer Network® (NCCN®) has updated the Clinical Practice Guidelines in oncology for breast cancer (Version 1.2019) to include scalp cooling as a Category 2A recommendation to reduce the incidence of chemotherapy-induced alopecia for patients receiving chemotherapy.

“As PAXMAN submitted an application for consideration to the NCCN Breast Cancer Panel last year, we are pleased to announce this major positive step towards a higher quality of life for breast cancer patients undergoing chemotherapy treatment. This recommendation by NCCN is an important step stone toward increasing patient and provider access to scalp cooling, as the majority of public and private payers recognize NCCN Guidelines as the gold standard for coverage and reimbursement policies in the US,” says PAXMAN's CEO Richard Paxman.

“PAXMAN is already the scalp cooling partner of choice for many leading cancer centers in the US, and we are experiencing a strong demand following our expanded FDA clearance last year. Broader payer coverage will help drive greater adoption by US cancer centers and growth in enrolment going forward,” says Richard Paxman.

PAXMAN is experiencing significant growth in the US, both in terms of installed systems and enrolled patients. To date, PAXMAN has around 380 scalp cooling systems installed in the US across 35 states and 199 locations.

For further information, please contact:
Richard Paxman, CEO
Tel: +44 7968 020641
E-mail: richard@paxmanscalpcooling.com
www.paxman.se

This information is information that PAXMAN AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16.30 CET on 17th March 2019.

About NCCN
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient and accessible cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world.

About PAXMAN
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,500 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling.
technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North. FNCA Sweden AB is the company’s Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.